Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$192.32 -1.4%	$187.01	$163.81 ▼ $218.66	$344.45B	0.48	6.30 million shs	4.99 million shs
AZN AstraZeneca	$71.13 -0.9%	$70.72	$61.24 ▼ $87.68	$222.71B	0.37	5.27 million shs	2.73 million shs
LLY Eli Lilly and Company	$793.34 +0.3%	$766.39	$677.09 ▼ $972.53	$749.33B	0.4	3.67 million shs	2.85 million shs
MRK Merck & Co., Inc.	$83.35 -0.8%	$79.08	$73.31 ▼ $129.93	$210.98B	0.39	13.42 million shs	9.72 million shs
NVS Novartis	$120.93 -2.3%	$116.01	$96.06 ▼ $124.83	$261.37B	0.59	1.59 million shs	2.75 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-1.35%	+1.49%	+0.55%	+9.96%	+14.38%
AZN AstraZeneca	-0.95%	+2.20%	-3.54%	+7.30%	-8.51%
LLY Eli Lilly and Company	+0.39%	+1.76%	-1.81%	+8.44%	-15.60%
MRK Merck & Co., Inc.	-0.84%	+2.94%	+3.84%	+5.32%	-34.54%
NVS Novartis	-2.23%	-0.80%	+2.50%	+12.45%	+10.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.4956 of 5 stars	2.4	3.0	3.3	3.9	3.2	1.7	1.3
AZN AstraZeneca	3.7562 of 5 stars	3.4	5.0	1.7	0.0	3.5	0.0	1.3
LLY Eli Lilly and Company	4.9827 of 5 stars	4.4	4.0	3.3	4.0	2.9	1.7	1.9
MRK Merck & Co., Inc.	4.9962 of 5 stars	3.2	4.0	5.0	4.2	3.4	2.5	3.8
NVS Novartis	1.5563 of 5 stars	1.0	3.0	2.5	0.0	2.8	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.81	Moderate Buy	$211.29	9.86% Upside
AZN AstraZeneca	2.83	Moderate Buy	$89.00	25.12% Upside
LLY Eli Lilly and Company	2.75	Moderate Buy	$1,012.56	27.63% Upside
MRK Merck & Co., Inc.	2.43	Hold	$108.69	30.40% Upside
NVS Novartis	2.00	Hold	$123.67	2.26% Upside

Current Analyst Ratings Breakdown

Latest ABBV, NVS, MRK, AZN, and LLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$936.00 ➝ $942.00
7/10/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$1,133.00 ➝ $1,135.00
7/10/2025	MRK Merck & Co., Inc.	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$99.00 ➝ $98.00
7/9/2025	AZN AstraZeneca	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$97.00
6/20/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$936.00
6/11/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$205.00
6/9/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold	$204.00
6/5/2025	LLY Eli Lilly and Company	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/14/2025	ABBV AbbVie	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$210.00 ➝ $205.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.03	$14.73 per share	13.06	$1.90 per share	101.22
AZN AstraZeneca	$54.07B	4.08	$6.23 per share	11.41	$13.18 per share	5.40
LLY Eli Lilly and Company	$45.04B	16.69	$14.28 per share	55.54	$15.03 per share	52.78
MRK Merck & Co., Inc.	$64.17B	3.26	$9.39 per share	8.88	$18.33 per share	4.55
NVS Novartis	$50.32B	5.08	$10.46 per share	11.56	$21.59 per share	5.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.35	81.84	13.76	1.29	7.31%	412.03%	13.11%	7/31/2025 (Estimated)
AZN AstraZeneca	$7.04B	$2.49	28.57	14.23	1.32	14.14%	33.14%	12.83%	7/29/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$12.29	64.55	25.49	1.16	22.67%	85.51%	15.74%	8/7/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	12.13	8.42	0.87	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
NVS Novartis	$11.94B	$6.40	18.90	13.73	1.70	24.70%	39.44%	16.43%	7/17/2025 (Estimated)

Latest ABBV, NVS, MRK, AZN, and LLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.56	N/A	N/A	N/A	$14.40 billion	N/A
7/29/2025	Q2 2025	AZN AstraZeneca	$1.11	N/A	N/A	N/A	$14.08 billion	N/A
7/29/2025	Q2 2025	MRK Merck & Co., Inc.	$2.03	N/A	N/A	N/A	$15.92 billion	N/A
7/24/2025	Q2 2025	ABBV AbbVie	$3.24	N/A	N/A	N/A	$14.93 billion	N/A
7/17/2025	Q2 2025	NVS Novartis	$2.37	N/A	N/A	N/A	$13.94 billion	N/A
5/1/2025	Q1 2025	LLY Eli Lilly and Company	$4.64	$3.34	-$1.30	$3.06	$12.77 billion	$12.73 billion
4/29/2025	Q1 2025	AZN AstraZeneca	$1.10	$1.24	+$0.14	$0.93	$13.71 billion	$13.59 billion
4/29/2025	Q1 2025	NVS Novartis	$2.12	$2.28	+$0.16	$1.83	$12.92 billion	$13.23 billion
4/25/2025	Q1 2025	ABBV AbbVie	$2.40	$2.46	+$0.06	$0.72	$12.91 billion	$13.34 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.41%	N/A	279.15%	53 Years
AZN AstraZeneca	$2.06	2.90%	N/A	82.73%	N/A
LLY Eli Lilly and Company	$6.00	0.76%	N/A	48.82%	11 Years
MRK Merck & Co., Inc.	$3.24	3.89%	N/A	47.16%	14 Years
NVS Novartis	$2.60	2.15%	N/A	40.63%	N/A

Latest ABBV, NVS, MRK, AZN, and LLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
6/20/2025	ABBV AbbVie	quarterly	$1.64	3.54%	7/15/2025	7/15/2025	8/15/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
5/5/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.73%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	44.14	0.76	0.64
AZN AstraZeneca	0.65	0.90	0.70
LLY Eli Lilly and Company	2.18	1.37	1.06
MRK Merck & Co., Inc.	0.69	1.41	1.16
NVS Novartis	0.56	0.79	0.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
AZN AstraZeneca	20.35%
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
NVS Novartis	13.12%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.25%
AZN AstraZeneca	N/A
LLY Eli Lilly and Company	0.13%
MRK Merck & Co., Inc.	0.13%
NVS Novartis	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	55,000	1.77 billion	1.76 billion	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
LLY Eli Lilly and Company	47,000	947.74 million	946.50 million	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable

ABBV, NVS, MRK, AZN, and LLY Headlines

Recent News About These Companies

Novartis AG (NYSE:NVS) Shares Sold by Bank of New York Mellon Corp

1 hour ago | marketbeat.com

Novartis Loses Bid to Halt Generic Drug Launch

July 11 at 4:27 PM | devdiscourse.comD

Court Rules Against Novartis: Generic Version of Entresto to Launch by 2026

July 11 at 4:27 PM | devdiscourse.comD

Novartis loses bid to block US Entresto generic through 2026

July 11 at 12:27 PM | reuters.com

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)

July 11 at 11:26 AM | theglobeandmail.com

Head to Head Survey: Novartis (NYSE:NVS) vs. Eli Lilly and Company (NYSE:LLY)

July 11 at 2:31 AM | americanbankingnews.com

Novartis (NYSE:NVS) Reaches New 1-Year High - Still a Buy?

July 10 at 2:16 PM | marketbeat.com

Parr Mcknight Wealth Management Group LLC Buys 3,149 Shares of Novartis AG (NYSE:NVS)

July 10 at 8:36 AM | marketbeat.com

Novartis AG (NYSE:NVS) Shares Sold by Brown Advisory Inc.

July 10 at 5:35 AM | marketbeat.com

Swissmedic approves Novartis’ Coartem Baby to treat malaria in newborns and young infants

July 10 at 3:35 AM | pharmabiz.comP

Novartis (NVS) to Release Quarterly Earnings on Thursday

July 10 at 2:42 AM | marketbeat.com

Drug manufacturer Novartis gets nod for first malaria drug to treat babies

July 9 at 5:34 PM | theweek.inT

Novartis inks $175M option deal for Sironax’s blood-brain barrier tech

July 9 at 5:34 PM | fiercebiotech.comF

Novartis' malaria drug for babies wins world-first approval

July 9 at 6:01 AM | fiercepharma.comF

Breakthrough for babies: Novartis Coartem Baby approved as first Malaria drug for Infants

July 9 at 6:01 AM | medicaldialogues.inM

Envestnet Asset Management Inc. Has $179.33 Million Stock Position in Novartis AG (NYSE:NVS)

July 9 at 5:32 AM | marketbeat.com

First infant malaria treatment receives approval: Novartis

July 8, 2025 | medicalxpress.comM

Novartis wins approval for first malaria drug for newborns and babies

July 8, 2025 | msn.com

Why Novartis (NVS) is a Top Value Stock for the Long-Term

July 8, 2025 | zacks.com

Novartis receives approval for first malaria medicine for newborns and infants

July 8, 2025 | thepharmaletter.comT

Novartis' Coartem Baby Gets Swissmedic Approval For Malaria In Newborn Babies, Young Infants

July 8, 2025 | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Are Growth Stocks Back? 3 That Look Like Winners to Buy Now
By Jeffrey Neal Johnson | July 10, 2025
View Are Growth Stocks Back? 3 That Look Like Winners to Buy Now
Could Meta and Eli Lilly Trigger the Next Stock Split Boom?
By Leo Miller | June 16, 2025
View Could Meta and Eli Lilly Trigger the Next Stock Split Boom?

ABBV, NVS, MRK, AZN, and LLY Company Descriptions

AbbVie NYSE:ABBV

$192.32 -2.68 (-1.37%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$192.38 +0.06 (+0.03%)

As of 07/11/2025 07:50 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AstraZeneca NASDAQ:AZN

$71.13 -0.68 (-0.95%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$71.41 +0.28 (+0.40%)

As of 07/11/2025 07:40 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Eli Lilly and Company NYSE:LLY

$793.34 +2.69 (+0.34%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$792.01 -1.33 (-0.17%)

As of 07/11/2025 08:00 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$83.35 -0.67 (-0.80%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$83.24 -0.11 (-0.14%)

As of 07/11/2025 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis NYSE:NVS

$120.93 -2.80 (-2.26%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$123.24 +2.32 (+1.91%)

As of 07/11/2025 07:27 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABBV, NVS, MRK, AZN, and LLY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABBV, NVS, MRK, AZN, and LLY Earnings

Compare Dividends

Latest ABBV, NVS, MRK, AZN, and LLY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABBV, NVS, MRK, AZN, and LLY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABBV, NVS, MRK, AZN, and LLY Company Descriptions

AbbVie NYSE:ABBV

AstraZeneca NASDAQ:AZN

Eli Lilly and Company NYSE:LLY

Merck & Co., Inc. NYSE:MRK

Novartis NYSE:NVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools